Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy

Cancer Letters

Volumn 364, Issue 2, 2015, Pages 135-141

  James, Mark I ^a   Iwuji, Chinenye ^a   Irving, Glen ^a   Karmokar, Ankur ^a   Higgins, Jennifer A ^a   Griffin Teal, Nicola ^a   Thomas, Anne ^a   Greaves, Peter ^a   Cai, Hong ^a   Patel, Samita R ^a   Morgan, Bruno ^a   Dennison, Ashley ^b   Metcalfe, Matthew ^b   Garcea, Giuseppe ^b   Lloyd, David M ^b   Berry, David P ^c   Steward, William P ^a   Howells, Lynne M ^a   Brown, Karen ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LEICESTER GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Cancer stem cells; Colorectal liver metastases; Combination therapy; Curcumin

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD133 ANTIGEN; CURCUMIN; FLUOROURACIL; OXALIPLATIN; ANTINEOPLASTIC AGENT; FOLINIC ACID; PLATINUM COMPLEX;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ANOREXIA; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLOATING; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CLINICAL ARTICLE; COLORECTAL LIVER METASTASIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENZYME ACTIVITY; EX VIVO STUDY; FATIGUE; FLATULENCE; HUMAN; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; NAUSEA; ORAL MUCOSITIS; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RASH; VOMITING; XEROSTOMIA; ANIMAL; APOPTOSIS; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; LIVER NEOPLASMS; METABOLISM; MOUSE; MULTICELLULAR SPHEROID; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; SECONDARY; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; COLORECTAL NEOPLASMS; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROURACIL; HETEROGRAFTS; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; ORGANOPLATINUM COMPOUNDS; SPHEROIDS, CELLULAR;

EID: 84930084889     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.05.005     Document Type: Article

References (46)

1. Excellence NIfC Colorectal cancer: the diagnosis and management of colorectal cancer http://www.nice.org.uk/Guidance/CG131.
2. National Cancer Institute National Cancer Institute: colon cancer treatment (accessed 13.05.14). http://cancer.gov/cancertopics/pdq/treatment/colon/HealthProfessional.
3. Irving G.R., Karmokar A., Berry D.P., et al. Curcumin: the potential for efficacy in gastrointestinal diseases. Best Pract. Res. Clin. Gastroenterol 2011, 25(4-5):519-534.
4. Howells L.M., Sale S., Sriramareddy S.N., et al. Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo. Int. J. Cancer 2011, 129(2):476-486.
5. Irving G.R., Howells L.M., Sale S., et al. Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration - a clinical pilot study including assessment of patient acceptability. Cancer Prev. Res 2013, 6(2):119-128.
6. Kim B., Giardiello F.M. Chemoprevention in familial adenomatous polyposis. Best Pract. Res. Clin. Gastroenterol 2011, 25(4-5):607-622. Epub 2011/11/30.
7. Carroll R.E., Benya R.V., Turgeon D.K., et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev. Res 2011, 4(3):354-364.
8. Garcea G., Berry D.P., Jones D.J., et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol. Biomarkers Prev 2005, 14(1):120-125.
9. Garcea G., Jones D.J., Singh R., et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br. J. Cancer 2004, 90(5):1011-1015.
10. He Z.Y., Shi C.B., Wen H., et al. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest 2011, 29(3):208-213.
11. Sharma R.A., Euden S.A., Platton S.L., et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res 2004, 10(20):6847-6854.
12. Dhillon N., Aggarwal B.B., Newman R.A., et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res 2008, 14(14):4491-4499.
13. Epelbaum R., Schaffer M., Vizel B., et al. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr. Cancer 2010, 62(8):1137-1141.
14. Kanai M., Otsuka Y., Otsuka K., et al. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother. Pharmacol 2013, 71(6):1521-1530.
15. Kanai M., Yoshimura K., Asada M., et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother. Pharmacol 2011, 68(1):157-164.
16. Bayet-Robert M., Kwiatkowski F., Leheurteur M., et al. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol. Ther 2010, 9(1):8-14.
17. Ghalaut V.S., Sangwan L., Dahiya K., et al. Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia. J. Oncol. Pharm. Pract 2012, 18(2):186-190.
18. Golombick T., Diamond T.H., Badmaev V., et al. The potential role of curcumin in patients with monoclonal gammopathy of undefined significance - its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker. Clin. Cancer Res 2009, 15(18):5917-5922.
19. Belcaro G., Hosoi M., Pellegrini L., et al. A controlled study of a lecithinized delivery system of curcumin (Meriva®) to alleviate the adverse effects of cancer treatment. Phytother. Res 2014, 28(3):444-450.
20. Ryan J.L., Heckler C.E., Ling M., et al. Curcumin for radiation dermatitis: a randomized, double-blind, placebo-controlled clinical trial of thirty breast cancer patients. Radiat. Res 2013, 180(1):34-43.
21. Norris L., Karmokar A., Howells L., et al. The role of cancer stem cells in the anti-carcinogenicity of curcumin. Mol. Nutr. Food Res 2013, 57(9):1630-1637. Epub 2013/08/01.
22. Kantara C., O'Connell M., Sarkar S., et al. Curcumin promotes autophagic survival of a subset of colon cancer stem cells, which are ablated by DCLK1-siRNA. Cancer Res 2014, 74(9):2487-2498. Epub 2014/03/15.
23. Zhang H., Yu T., Wen L., et al. Curcumin enhances the effectiveness of cisplatin by suppressing CD133 cancer stem cells in laryngeal carcinoma treatment. Exp. Ther. Med 2013, 6(5):1317-1321. Epub 2013/11/14.
24. Bao B., Ahmad A., Azmi A.S., et al. Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy 2013, Current protocols in pharmacology/editorial board, SJ Enna, Chapter 14:Unit 14 25. [Epub 2013/06/08.
25. Elshamy W.M., Duhe R.J. Overview: cellular plasticity, cancer stem cells and metastasis. Cancer Lett 2013, 341(1):2-8. Epub 2013/06/26.
26. James M.I., Howells L.M., Karmokar A., et al. Characterization and propagation of tumor initiating cells derived from colorectal liver metastases: trials, tribulations and a cautionary note. PLoS ONE 2015, 10(2):e0117776.
27. Chan A.W., Tetzlaff J.M., Altman D.G., et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann. Intern. Med 2013, 158(3):200-207.
28. Irving G., Iwuji C., Morgan B., et al. Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial. Trials 2015, 16:110.
29. Perkins S., Verschoyle R.D., Hill K., et al. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol. Biomarkers Prev 2002, 11(6):535-540.
30. Pettan-Brewer C., Morton J., Mangalindan R., et al. Curcumin suppresses intestinal polyps in APC Min mice fed a high fat diet. Pathobiol. Aging Age Relat. Dis 2011, 1.
31. Shehzad A., Lee J., Huh T.L., et al. Curcumin induces apoptosis in human colorectal carcinoma (HCT-15) cells by regulating expression of Prp4 and p53. Mol. Cells 2013, 35(6):526-532.
32. Howells L.M., Mitra A., Manson M.M. Comparison of oxaliplatin- and curcumin-mediated antiproliferative effects in colorectal cell lines. Int. J. Cancer 2007, 121(1):175-183.
33. Commandeur S., de Gruijl F.R., Willemze R., et al. An in vitro three-dimensional model of primary human cutaneous squamous cell carcinoma. Exp. Dermatol 2009, 18(10):849-856.
34. Hovinga K.E., Shimizu F., Wang R., et al. Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 2010, 28(6):1019-1029.
35. Shimizu F., Hovinga K.E., Metzner M., et al. Organotypic explant culture of glioblastoma multiforme and subsequent single-cell suspension. Current protocols in stem cell biology 2011, Chapter 3:Unit3 5.
36. Kanwar S.S., Yu Y., Nautiyal J., et al. Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm. Res 2011, 28(4):827-838.
37. Patel B.B., Gupta D., Elliott A.A., et al. Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Res 2010, 30(2):319-325.
38. Patel B.B., Sengupta R., Qazi S., et al. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int. J. Cancer 2008, 122(2):267-273.
39. Yu Y., Kanwar S.S., Patel B.B., et al. Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX. Transl. Oncol 2009, 2(4):321-328.
40. Sinicrope F.A. DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat. Rev. Clin. Oncol 2010, 7(3):174-177.
41. Kwon H.C., Roh M.S., Oh S.Y., et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann. Oncol 2007, 18(3):504-509.
42. Partridge A.H., Avorn J., Wang P.S., Winer E.P. Adherence to therapy with oral antineoplastic agents. J. Natl Cancer Inst 2002, 94(9):652-661.
43. Krolop L., Ko Y.D., Schwindt P.F., et al. Adherence management for patients with cancer taking capecitabine: a prospective two-arm cohort study. BMJ Open 2013, 3(7).
44. Allegra C.J., Yothers G., O'Connell M.J., et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J. Clin. Oncol 2009, 27(20):3385-3390.
45. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol 2004, 22(2):229-237.
46. Saltz L.B., Clarke S., Diaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol 2008, 26(12):2013-2019.